Systematic review of prenatal exposure to endocrine disrupting chemicals and autism spectrum disorder in offspring.
Current evidence linking prenatal endocrine disruptors to autism is methodologically weak—demand better-controlled studies before drawing practice conclusions.
01Research in Context
What this study did
Marí-Bauset et al. (2022) hunted for every paper that tested prenatal endocrine-disrupting chemicals and later autism.
They screened lab studies and human studies, then graded each one for quality.
The goal: see if the chemical-autism link is strong enough to guide practice.
What they found
Most studies were small or poorly controlled.
The team rated the overall evidence as “moderate quality, limited strength.”
In plain words: the link is still a maybe, not a yes.
How this fits with other research
MO et al. (2022) narrows the lens to one chemical—diethylstilbestrol—and still sees a signal. Salvador’s wider sweep says the same signal gets fuzzy when you add other chemicals.
Hung et al. (2023) found a tiny autism bump after labor epidurals, but call the evidence “very low quality.” Salvador’s verdict echoes that caution: weak methods everywhere.
Nutor et al. (2024) shows no autism rise after prenatal cannabis once tobacco is ruled out. Their tight control supports Salvador’s call for better-designed studies before we blame any single substance.
Why it matters
You will meet parents who swear a plastic smell or old pesticide caused their child’s autism. This review gives you calm, evidence-based language: “The data aren’t strong enough to name a culprit, but we’re watching.” Use the moment to steer families toward proven actions—early screening, ABA, and healthy homes—instead of guilt or unproven detox diets.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →When parents ask about plastics or pesticides, show the one-page summary of Salvador et al. (2022) and pivot to early-intervention enrollment.
02At a glance
03Original abstract
Autism spectrum disorders comprise a complex group with many subtypes of behaviorally defined neurodevelopmental abnormalities in two core areas: deficits in social communication and fixated, restricted, repetitive, or stereotyped behaviors and interests each with potential unique risk factors and characteristics. The underlying mechanisms and the possible causes of autism spectrum disorder remain elusive and while increased prevalence is undoubtable, it is unclear if it is a reflection of diagnostic improvement or emerging risk factors such as endocrine disrupting chemicals. Epidemiological studies, which are used to study the relation between endocrine disrupting chemicals and autism spectrum disorder, can have inherent methodological challenges that limit the quality and strength of their findings. The objective of this work is to systematically review the treatment of these challenges and assess the quality and strength of the findings in the currently available literature. The overall quality and strength were "moderate" and "limited," respectively. Risk of bias due to the exclusion of potential confounding factors and the lack of accuracy of exposure assessment methods were the most prevalent. The omnipresence of endocrine disrupting chemicals and the biological plausibility of the association between prenatal exposure and later development of autism spectrum disorder highlight the need to carry out well-designed epidemiological studies that overcome the methodological challenges observed in the currently available literature in order to be able to inform public policy to prevent exposure to these potentially harmful chemicals and aid in the establishment of predictor variables to facilitate early diagnosis of autism spectrum disorder and improve long-term outcomes.
Autism : the international journal of research and practice, 2022 · doi:10.1177/13623613211039950